<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Preeclampsia</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Sam Ashoo, MD</div><div><strong>Updated:</strong> <!-- -->3/1/2018</div></div><div class="card__content"><h1 id="preeclampsia">Preeclampsia</h1>
<p>Preeclampsia is on a spectrum of pregnancy related illness which includes eclampsia and HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets - debate exists about if this is a separate entity altogether). Without intervention, it can lead to seizures (eclampsia) and carries a high mortality for mom and baby. </p>
<p>A pregnancy-related condition occurring anytime after 20 weeks pregnancy and up to 6 weeks postpartum, it is diagnosed by elevated blood pressure and and least one associated finding.</p>
<h2 id="criteria">Criteria</h2>
<ul>
<li>Pregnancy, 20 weeks gestation up to 6 weeks post partum, </li>
<li><strong>AND</strong> Hypertension &gt;140/90 x 2 (at least 4 hours apart) or &gt;160/110 x 2 (minutes apart) in a woman who was previously normotensive</li>
<li><strong>AND</strong> any one of the following<ul>
<li>Proteinuria, defined as urine dipstick &gt;1+ or &gt;0.3 g in a 24-hour period</li>
<li>Platelets &lt;100k/mcL</li>
<li>Serum creatinine &gt; 1.1 mg/dL</li>
<li>Liver transaminases at least 2 times normal</li>
<li>Severe right upper quadrant or epigastric pain, not explained by another diagnosis</li>
<li>Pulmonary edema</li>
<li>Visual symptoms (e.g. blurred vision, flashing lights or sparks, scotoma)</li>
<li>Cerebral symptoms (e.g. severe persistent headache not responding to usual doses of analgesics)</li>
</ul>
</li>
</ul>
<h2 id="treatment">Treatment</h2>
<ul>
<li>Delivering placenta resolves symptoms in 48 hours in most cases (except postpartum cases)</li>
<li><span class="drug">Magnesium Sulfate</span> IV for seizure prevention:<ul>
<li>Loading dose: 4-6 g loading dose</li>
<li>Followed by continuous infusion: 1-2 g/hour for at least 24 hours</li>
</ul>
</li>
<li>BP management until systolic &lt; 150 and diastolic &lt; 100<ul>
<li><span class="drug">Labetalol</span> 20 mg IV every 10 min (max 80mg per dose) for a total of 300mg.</li>
<li><span class="drug">Hydralazine</span> 5 mg IV, repeat in 20 min until goal achieved, max 30mg. </li>
<li><span class="drug">Nicardipine</span> infusion 3-9 mg hour</li>
<li><span class="drug">Nitroglycerin</span> IV if pulmonary edema</li>
</ul>
</li>
<li>Corticosteroids if &lt; 34 weeks gestation and delivery anticipated in next 48 hours.<ul>
<li><span class="drug">Betamethasone</span>: Two doses of 12 mg given intramuscularly 24 hours apart <strong>OR</strong></li>
<li><span class="drug">Dexamethasone</span> (sodium phosphate): Four doses of 6 mg given intramuscularly 12 hours apart. A non-sulfite containing preparation should be used as the sulfite preservative commonly used in dexamethasone preparations may be directly neurotoxic in newborns.</li>
</ul>
</li>
</ul>
<h2 id="symptoms">Symptoms</h2>
<ul>
<li>Severe headache</li>
<li>Visual changes</li>
<li>Upper abdominal pain</li>
<li>Nausea or vomiting</li>
<li>Shortness of breath</li>
<li>Chest pain</li>
<li>Altered mental status</li>
</ul>
<h2 id="risk-factors">Risk Factors</h2>
<ul>
<li>A past history of pre-eclampsia confers a 7-fold risk</li>
<li>First-time pregnancy</li>
<li>Twin pregnancies</li>
<li>Family history in first-degree relative</li>
<li>Advanced maternal age (&gt; 40 years)</li>
<li>Pre-gestational diabetes mellitus</li>
<li>Hypertension</li>
<li>Antiphospholipid antibody</li>
<li>Obesity (BMI&gt;25) (14)</li>
<li>Chronic kidney disease</li>
</ul>
<h2 id="complications">Complications</h2>
<p>Women with preeclampsia have increased risk of:</p>
<ul>
<li>Congestive heart failure</li>
<li>Disseminated intravascular coagulation</li>
<li>Intracranial hemorrhage </li>
<li>Liver failure or rupture</li>
<li>Placental abruption</li>
<li>Pulmonary edema</li>
<li>Renal failure</li>
<li>Seizure</li>
<li>Stroke</li>
<li>Death<ul>
<li>Worldwide 10-15% of maternal death from obstetric cause is due to preeclampsia/eclampsia [2]</li>
<li>In the U.S., it is one of 4 causes of obstetric deaths (hemorrhage, cardiovascular conditions, thromboembolism). 1 death / 100,000 births.  [12]</li>
<li>Fatality is 6.4 deaths/10,000 [13]</li>
</ul>
</li>
</ul>
<p>When does it happen and how often?</p>
<ul>
<li>After 20 weeks gestation and as late as 6 weeks post partum [1]</li>
<li>3-4% of all pregnancies in the U.S. and 4-5% worldwide [3]</li>
<li>Almost 2 times higher prevalence in first pregnancy [3]</li>
<li>Consider molar pregnancy if they are less than 20 weeks with criteria [11]</li>
</ul>
<h2 id="references">References</h2>
<ol>
<li>The American College of Obstetricians and Gynecologists- Task Force on Hypertension in Pregnancy. Hypertension in pregancy. In : LIbrarY oF conGress cataLoGInG-In- PubLIcatIon data, 2013. [<a href="https://www.acog.org/~/media/Task%20Force%20and%20Work%20Group%20Reports/public/HypertensioninPregnancy.pdf">ACOG</a>]</li>
<li>Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130-7.  [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=19464502">PubMed</a>]</li>
<li>Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013;347:f6564.  [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=24201165">PubMed</a>]</li>
<li>Schutte JM, Steegers EA, Schuitemaker NW, et al. Rise in maternal mortality in the Netherlands. BJOG. 2010;117(4):399-406.  [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=19943828">PubMed</a>]</li>
<li>Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565.  [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=15743856">PubMed</a>]</li>
<li>Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341(8858):1447-51.  [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=8099148">PubMed</a>]</li>
<li>Meekins JW, Pijnenborg R, Hanssens M, Mcfadyen IR, Van asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1994;101(8):669-74.  [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=7947500">PubMed</a>]</li>
<li>Bar-lev MR, Maayan-metzger A, Matok I, Heyman Z, Sivan E, Kuint J. Short-term outcomes in low birth weight infants following antenatal exposure to betamethasone versus dexamethasone. Obstet Gynecol. 2004;104(3):484-8. [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=15339757">PubMed</a>]</li>
<li>Walfisch A, Hallak M, Mazor M. Multiple courses of antenatal steroids: risks and benefits. Obstet Gynecol. 2001;98(3):491-7. [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=11530136">PubMed</a>]</li>
<li>August, P. Management of hypertension in pregnant and postpartum women. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2018.[<a href="https://www.uptodate.com/contents/management-of-hypertension-in-pregnant-and-postpartum-women?search=preeclampsia%20treatment&amp;source=search_result&amp;selectedTitle=2~150&amp;usage_type=default&amp;display_rank=2">UpToDate</a>]</li>
<li>August, P. Preeclampsia: Clinical features and diagnosis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2018.[<a href="https://www.uptodate.com/contents/preeclampsia-clinical-features-and-diagnosis?search=preeclampsia&amp;source=search_result&amp;selectedTitle=1~150&amp;usage_type=default&amp;display_rank=1">UpToDate</a>]</li>
<li>Chang J, Elam-evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ. 2003;52(2):1-8.  [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=12825542">PubMed</a>]</li>
<li>Mackay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol. 2001;97(4):533-8. [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=11275024">PubMed</a>]</li>
<li>Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753. [<a href="https://www.ncbi.nlm.nih.gov/pubmed?term=27094586">PubMed</a>]</li>
</ol>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"preeclampsia","title":"Preeclampsia","authors":["Sam Ashoo, MD"],"categories":[{"slug":"obgyn","name":"OBGYN"}],"created":"2018/03/01","updated":"2018/05/14","body":"\n# Preeclampsia\n\nPreeclampsia is on a spectrum of pregnancy related illness which includes eclampsia and HELLP syndrome (Hemolysis, Elevated Liver enzymes, Low Platelets - debate exists about if this is a separate entity altogether). Without intervention, it can lead to seizures (eclampsia) and carries a high mortality for mom and baby. \n\nA pregnancy-related condition occurring anytime after 20 weeks pregnancy and up to 6 weeks postpartum, it is diagnosed by elevated blood pressure and and least one associated finding.\n\n## Criteria\n\n- Pregnancy, 20 weeks gestation up to 6 weeks post partum, \n- **AND** Hypertension \u003e140/90 x 2 (at least 4 hours apart) or \u003e160/110 x 2 (minutes apart) in a woman who was previously normotensive\n- **AND** any one of the following\n  - Proteinuria, defined as urine dipstick \u003e1+ or \u003e0.3 g in a 24-hour period\n  - Platelets \u003c100k/mcL\n  - Serum creatinine \u003e 1.1 mg/dL\n  - Liver transaminases at least 2 times normal\n  - Severe right upper quadrant or epigastric pain, not explained by another diagnosis\n  - Pulmonary edema\n  - Visual symptoms (e.g. blurred vision, flashing lights or sparks, scotoma)\n  - Cerebral symptoms (e.g. severe persistent headache not responding to usual doses of analgesics)\n\n## Treatment\n\n- Delivering placenta resolves symptoms in 48 hours in most cases (except postpartum cases)\n- \u003cspan class=\"drug\"\u003eMagnesium Sulfate\u003c/span\u003e IV for seizure prevention:\n  - Loading dose: 4-6 g loading dose\n  - Followed by continuous infusion: 1-2 g/hour for at least 24 hours\n- BP management until systolic \u003c 150 and diastolic \u003c 100\n  - \u003cspan class=\"drug\"\u003eLabetalol\u003c/span\u003e 20 mg IV every 10 min (max 80mg per dose) for a total of 300mg.\n  - \u003cspan class=\"drug\"\u003eHydralazine\u003c/span\u003e 5 mg IV, repeat in 20 min until goal achieved, max 30mg. \n  - \u003cspan class=\"drug\"\u003eNicardipine\u003c/span\u003e infusion 3-9 mg hour\n  - \u003cspan class=\"drug\"\u003eNitroglycerin\u003c/span\u003e IV if pulmonary edema\n- Corticosteroids if \u003c 34 weeks gestation and delivery anticipated in next 48 hours.\n  - \u003cspan class=\"drug\"\u003eBetamethasone\u003c/span\u003e: Two doses of 12 mg given intramuscularly 24 hours apart **OR**\n  - \u003cspan class=\"drug\"\u003eDexamethasone\u003c/span\u003e (sodium phosphate): Four doses of 6 mg given intramuscularly 12 hours apart. A non-sulfite containing preparation should be used as the sulfite preservative commonly used in dexamethasone preparations may be directly neurotoxic in newborns.\n\n## Symptoms\n\n- Severe headache\n- Visual changes\n- Upper abdominal pain\n- Nausea or vomiting\n- Shortness of breath\n- Chest pain\n- Altered mental status\n\n## Risk Factors\n\n- A past history of pre-eclampsia confers a 7-fold risk\n- First-time pregnancy\n- Twin pregnancies\n- Family history in first-degree relative\n- Advanced maternal age (\u003e 40 years)\n- Pre-gestational diabetes mellitus\n- Hypertension\n- Antiphospholipid antibody\n- Obesity (BMI\u003e25) (14)\n- Chronic kidney disease\n\n## Complications\n\nWomen with preeclampsia have increased risk of:\n\n- Congestive heart failure\n- Disseminated intravascular coagulation\n- Intracranial hemorrhage \n- Liver failure or rupture\n- Placental abruption\n- Pulmonary edema\n- Renal failure\n- Seizure\n- Stroke\n- Death\n  - Worldwide 10-15% of maternal death from obstetric cause is due to preeclampsia/eclampsia [2]\n  - In the U.S., it is one of 4 causes of obstetric deaths (hemorrhage, cardiovascular conditions, thromboembolism). 1 death / 100,000 births.  [12]\n  - Fatality is 6.4 deaths/10,000 [13]\n\nWhen does it happen and how often?\n\n- After 20 weeks gestation and as late as 6 weeks post partum [1]\n- 3-4% of all pregnancies in the U.S. and 4-5% worldwide [3]\n- Almost 2 times higher prevalence in first pregnancy [3]\n- Consider molar pregnancy if they are less than 20 weeks with criteria [11]\n\n## References\n\n1. The American College of Obstetricians and Gynecologists- Task Force on Hypertension in Pregnancy. Hypertension in pregancy. In : LIbrarY oF conGress cataLoGInG-In- PubLIcatIon data, 2013. [[ACOG](https://www.acog.org/~/media/Task%20Force%20and%20Work%20Group%20Reports/public/HypertensioninPregnancy.pdf)]\n2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol. 2009;33(3):130-7.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=19464502)]\n3. Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980-2010: age-period-cohort analysis. BMJ. 2013;347:f6564.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=24201165)]\n4. Schutte JM, Steegers EA, Schuitemaker NW, et al. Rise in maternal mortality in the Netherlands. BJOG. 2010;117(4):399-406.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=19943828)]\n5. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal booking: systematic review of controlled studies. BMJ. 2005;330(7491):565.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=15743856)]\n6. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341(8858):1447-51.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=8099148)]\n7. Meekins JW, Pijnenborg R, Hanssens M, Mcfadyen IR, Van asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1994;101(8):669-74.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=7947500)]\n8. Bar-lev MR, Maayan-metzger A, Matok I, Heyman Z, Sivan E, Kuint J. Short-term outcomes in low birth weight infants following antenatal exposure to betamethasone versus dexamethasone. Obstet Gynecol. 2004;104(3):484-8. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=15339757)]\n9. Walfisch A, Hallak M, Mazor M. Multiple courses of antenatal steroids: risks and benefits. Obstet Gynecol. 2001;98(3):491-7. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=11530136)]\n10. August, P. Management of hypertension in pregnant and postpartum women. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2018.[[UpToDate](  https://www.uptodate.com/contents/management-of-hypertension-in-pregnant-and-postpartum-women?search=preeclampsia%20treatment\u0026source=search_result\u0026selectedTitle=2~150\u0026usage_type=default\u0026display_rank=2)]\n11. August, P. Preeclampsia: Clinical features and diagnosis. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2018.[[UpToDate](https://www.uptodate.com/contents/preeclampsia-clinical-features-and-diagnosis?search=preeclampsia\u0026source=search_result\u0026selectedTitle=1~150\u0026usage_type=default\u0026display_rank=1)]\n12. Chang J, Elam-evans LD, Berg CJ, et al. Pregnancy-related mortality surveillance--United States, 1991--1999. MMWR Surveill Summ. 2003;52(2):1-8.  [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=12825542)]\n13. Mackay AP, Berg CJ, Atrash HK. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol. 2001;97(4):533-8. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=11275024)]\n14. Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ. 2016;353:i1753. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed?term=27094586)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"preeclampsia"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>